with World Health Organization (WHO) group I and II ovulatory disorders. 1 Purified preparation of FSH was also generated as a drug for WHO group II patients who did not need additional LH activity because their serum levels of LH remained adequate for the follicular development. Although hMG and FSH were derived from the urine of menopausal women, recombinant FSH has been generated using biotechnology and has contributed to the improvement of the quality and the clinical availability of the product. These gonadotropin drugs are used not only for ovulation induction (OI) in ovulatory disorders but also for ovarian stimulation (OS) in unexplained infertility 2 and OS in assisted reproductive technology (ART). 3 On the other hand, infertility treatment, especially gonadotropin therapy, has brought serious side effects such as multiple pregnancy and ovarian hyperstimulation syndrome (OHSS). In the 1970s, multiple pregnancy and severe OHSS rate were reported to be 36.3% and 3.9%, respectively, in 41 clomiphene-resistant PCOS patients treated with hMG-hCG. 4 Multiple pregnancy has a negative impact on maternal health and the long-term outcome of the infants, as well as imposing a significant burden on neonatal practice.
OI by gonadotropin easily leads to multiple follicular development and multiple ovulation which are responsible for the multiple pregnancy. Controlling the serum FSH level suitable for monofollicular development is not easy because the negative feedback system does not work adequately in anovulatory patients, and therefore the dose of hMG or FSH often becomes excessive and multiple follicles develop. Based on the FSH threshold concept, 5 minimizing the dose of FSH seems to be effective in facilitating monofollicular growth and reducing the risk of multiple pregnancy associated with OI. Since a chronic low dose FSH regimen was reported in 5 PCOS women in 1984, 6 this type of regimen for OI has been reported to reduce multiple pregnancy. [7] [8] [9] [10] In the low dose step-up regimen, the starting daily dose of FSH was 37.5 IU, 50 IU or 75 IU. The daily dose was increased by almost half of the starting dose; 25 IU or 37.5 IU, if no follicle developed after 7 days of administration, or after 14 days in the "chronic" protocol. Dose increment was considered weekly usually up to 4 times. The incidence of multiple pregnancy following OI is reported to be 5.7% in low dose FSH therapy. 10 However, this percentage might not be sufficient in comparison with recent ART, where elective single-embryo transfer (eSET) has become common and the multiple pregnancy rate has markedly reduced to 3.1% in fresh cycles and 3.2% in frozen cycles in 2015 in Japan. 11, 12 Additionally, FSH or hMG, with or without intrauterine insemination (IUI), has been used for OS as an empiric therapy in patients with unexplained infertility who have normal FSH secretion. 2 OS, injecting FSH to women with unexplained fertility, results in higher serum levels of FSH allowing multiple follicular development, which might expand the chance of conceiving as well as increase a risk of multiple pregnancy.
There is evidence that women with a lower body mass index (BMI) are more likely to show an excessive ovarian response to OI, whereas women with a higher BMI generally require higher total gonadotropin doses for inducing follicular development and ovulation. 13 The devise used for subcutaneous self-injection (Gonalef ® Pen; Merk Serono Co., Ltd., Tokyo, Japan) of recombinant FSH was recently renewed, and this has allowed us to adjust the FSH dose in smaller steps of 12.5 IU. In this study, we planned and tested an optimized protocol of FSH therapy that has an individualized starting dose based on BMI and a fine incremental doses as low as 12.5 IU for infertile women with an ovulatory disorder and unexplained infertility in order to facilitate a monofollicular ovarian response.
| MATERIAL S AND ME THODS

| Study design
This study was a prospective interventional trial.
| Patients
Fifty infertile patients were enrolled in this study, including anovulatory women with WHO group II ovarian insufficiency for whom OI was indicated (OI patients, n = 29), and eumenorrheic women with a diagnosis of unexplained infertility for whom OS was indicated (OS patients, n = 21). These subjects were divided into groups by BMI, (BMI < 20 groups and BMI ≥ 20 groups) for selecting the initial FSH dose in the treatment described below (Section 2.3.). Each patient received only one cycle of the low dose step-up FSH therapy in this study, because we believe that multiple cycles treatment to the same patient is not fair due to the dose individualization in the following cycles and/or dropout of the patients who experienced unfavorable outcome in the first cycle preventing precise estimation of the protocol.
World Health Organization group II ovarian insufficiency consisted of amenorrhea (amenorrhea more than 6 months), oligomenorrhea (menstrual cycle more than 38 days), and anovulatory cycles (normal cycle length of 25-38 days without ovulation) which were diagnosed using the Japan Society of Obstetrics and Gynecology (JSOG) criteria. 14 The OI group included 20 patients with polycystic ovary syndrome (PCOS). Diagnosis of PCOS was made using the criteria of JSOG 14 , which means that the PCOS patients in this study also met the Rotterdam criteria. 15 Unexplained infertility was defined as not having apparent causes of infertility such as ovarian, male, and tubal factors. The OS patients had a regular menstruation of 25-38 days cycle with a biphasic pattern of basal body temperature, and had normal luteal function (mid-luteal progesterone [P4] concentration >5 ng/mL besides luteal phase length >10 days before registration). 16 Two of the OI patients enrolled were ineligible because they appeared to have WHO class I ovarian insufficiency. Therefore, these 2 patients were excluded, leaving 48 patients evaluable for the study.
One of the 2 excluded patients was a 33-year-old woman with a BMI continued, and administration of hCG was cancelled to reduce the incidence of multiple pregnancy. 17 Additionally, IUI was scheduled on the day after the hCG injection based on their own choice considering the couple's convenience and the duration of infertility.
| Transvaginal ultrasonography
The ovaries and follicular development were evaluated using transvaginal US with a 7.5 MHz transducer (Sonovista FX; Siemens Healthcare K.K., Tokyo, Japan). Ovarian volume per ovary (OVPO) was evaluated by the same gynecologist (T. M.) at the starting day of the FSH treatment and determined by the following formula: 0.5 × length × width × thickness. 18 OVPO associates with serum anti-Müllerian Hormone (AMH) level in PCOS, 19 which reflects ovarian reserve and could influence on the ovarian response to FSH.
OVPO ≥10 cm 3 was reported to be one of the definitive factors and had 100% specificity to distinguish PCOS. 18 All of the patients with OVPO ≥10 cm 3 in the present study had PCOS. 
| Blood sampling and hormone assay
| Study variables
| Demographic and clinical characteristics
Demographic profile (age, height, weight, BMI), history of infertility (duration, previous treatment, the presence of male factor and tubal factor in order to diagnose unexplained infertility), serum levels of hormones (FSH, LH, E2, P4, T, and AMH), and transvaginal US finding including polycystic ovarian morphology and ovarian volume both of which are essential for the diagnosis of PCOS, were summarized. 
| Outcomes of the treatment, efficacy, and safety
| Demographic and baseline parameters influencing/predicting treatment outcomes in OI
The relationship between the number of developing follicles (0-2) or daily dose of FSH that was effective to induce monfollicular development (FSH threshold) and multiple factors, such as demographic/ baseline parameters and serum hormone concentrations during the study, was analyzed in OI patients. Thereafter, multiple regression analysis was tried using the factors that showed a significant relationship with the FSH threshold which is a final daily FSH dose in the cycle achieving monofollicular development.
| Statistical analysis
Difference in values between the groups were analyzed using Statistical significance was defined as P < .05.
| Ethics
This study was approved by the Ethical Committee of Tokushima University Hospital (approval No. 2075) and written informed consent was obtained from all the participants.
| RE SULTS
Background data of the subjects are shown in Table 1 . There was no significant difference between the BMI < 20 group and BMI ≥ 20 group in the OI or OS patients. Although this study did not intend to compare the data of the OI patients with the OS patients, several elements in their background showed significant differences between them. The duration of infertility was longer in the OS patients than in the OI patients because anovulatory women in the OI would be aware that they had difficulty in conceiving, and therefore, would consult a clinic earlier than women with unexplained infertility in the OS. The BMI ≥ 20 group in OS had significantly higher mean age compared with the other 3 subgroups (P < .01). The OI patients showed relatively larger OVPO especially in BMI ≥ 20 patients (P < .01) and tended to have higher serum AMH concentration, because 20 of 27 in the OI patients were PCOS, having enlarged ovaries. All of the patients with OVPO ≥10 cm 3 in the present study were PCOS patients.
As for the administration of FSH in the OI patients, the BMI ≥ 20 group tended to be greater in the parameters than in the BMI < 20 group regarding the number of FSH doses increased, the total dose, or the number of days of FSH treatment, although the differences were not significant ( Table 2 ). The dose up times in OI were summarized in Tables 3 and 4 . Two or more dose increments were needed in 0% (0/5) of the BMI < 20 group and 22.7% (5/22) of the BMI ≥ 20 group (Table 3) . When BMI ≥ 20 group was divided into 3 subgroups by BMI, 2 or more dose increments were needed in 10.0% (1/10), 28.6% (2/7), and 40.0% (2/5, both of these patients failed to respond to FSH) of 20 ≤ BMI < 25, 25 ≤ BMI < 30, and BMI ≥ 30 subgroups, respectively (Table 4) . However, even with BMI ≥ 30, 2 patients did not require any dose increment. Difference between BMI subgroups was not significant by chi-squared test due to the low number of patients for the statistical analysis. On the other hand, in the OS patients, there was no significant difference between the BMI < 20
group and the BMI ≥ 20 group for the parameters of FSH administration (Table 2) , and all the patients did not need 2 or more dose increments ( Table 5) .
As for the clinical outcome of the OI patients, ovulation rate was 100% in the BMI < 20 group and ≥90% in the BMI ≥ 20 group (Table 6 ). In the 2 patients who failed to achieve ovulation, no follicle grew over 10 mm in diameter even after 3 or 4 times of the BMI < 20 group and 18.2% (4/22) in the BMI ≥ 20 group. All 7 pregnancies achieved in the OI patients were singleton. There was no cycle of hCG cancellation due to excessive response, and no incidence of moderate or severe OHSS and also no mild OHSS.
The other adverse reaction to FSH was genital bleeding with no response of the ovary, which was reported in one patient receiving the OI treatment.
In the OS patients, ovulation rate was 100% in both the BMI < 20 of developing follicles (≥16 mm in diameter) and various factors, such as demographic and baseline parameters, were analyzed ( Table 7) .
As a result, BMI was the only factor showing a significant correlation with the number of the developing follicles (r = −.410, P < .05).
Among the OI patients who achieved monofollicular development, the relationship between the final daily dose of FSH that was effective to induce monofollicular development (FSH threshold) and demographic/baseline parameters was analyzed (Table 8 ). Body mass index was the only factor showing a significant correlation with the FSH threshold (r = −.503, P < .05), whereas age almost reached significance (r = −.428, P = .053). When a multiple regression analysis was performed using a model with the FSH threshold as a response variable and with BMI and age as explanatory variables, there was no significant association between the FSH threshold and BMI or age (Table 9 ). On the other hand, no parameter was significantly correlated with the number of developing follicles in the OS patients based on Spearman/Pearson correlation analysis (data not shown). 
| D ISCUSS I ON
Multiple pregnancy is a major side effect of gonadotropin therapy that is derived from multifollicular development due to injection of excessive dose of FSH. Low dose step-up regimen of FSH was constructed as a safe method for WHO group II anovulatory patients, and has contributed to reduce the incidence of multiple pregnancy. We designed the new fine protocol of low dose step-up FSH therapy to reduce multifollicular development and the rate of multiple pregnancy. As a result, this protocol was highly effective to achieve monofollicular development and completely avoided the cancellation of the cycle due to excessive response and the complications of multiple pregnancy and/or OHSS, while having high rates of ovulation and pregnancy in WHO group II anovulatory patients.
Principle of low dose step-up FSH therapy was supported by FSH threshold concept. 5 In order to achieve monofolliclar develop- 26 Multiple pregnancy still seems to be problematic in OS treatment for unexplained infertility. In the present study, we tried mild stimulation in patients with unexplained infertility to prevent multiple pregnancy. As a result, no patient required 2 dose up times or more, and all patients ovulated with predominant monofollicular cycle (85.7% in BMI < 20 group and 78.6% in BMI ≥ 20 group).
However, none of the 21 patients with unexplained infertility conceived. After the study, all 21 patients continued OS with or without IUI, and only 1 patient conceived to date in a total of 75 cycles with 4 cancelled cycles due to no response. It is assumed that mild stimulation by our protocol is not suitable for patients with unexplained infertility. If multiple ovulation itself might enhance the chance of pregnancy, reducing the incidence of multiple pregnancy might be misguided, and elective single-embryo transfer in ART would be the only solution of the problem especially for patients with relatively long infertility period such as our subjects in this study.
In conclusion, low dose, step-up treatment with FSH starting with a BMI-based starting dose (50 IU for BMI < 20 and 62.5 IU for BMI ≥ 20) with a small increment dose (12.5 IU) was a safe and effective protocol for OI in patients with WHO group II ovulatory disorder. In overweight and obese patients, who require 2 or more dose escalations, the starting dose of FSH for the following cycle should be individualized. On the other hand, mild stimulation using this protocol might not be useful for patients with unexplained infertility having relatively long infertility period.
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